Onderneming Nymox Pharmaceutical Corporation Nasdaq
Aandelen
CA67076P1027
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
|
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 30-05-95 |
Patrick Doody
BRD | Director/Board Member | - | 12-07-23 |
Director/Board Member | - | 21-03-23 | |
Suresh Kalbag
PRN | Corporate Officer/Principal | - | - |
General Counsel | - | 06-02-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 08-06-06 |
Paul Averback
CEO | Chief Executive Officer | 73 | 30-05-95 |
Director/Board Member | 88 | 01-07-15 | |
Director/Board Member | - | 21-03-23 | |
Patrick Doody
BRD | Director/Board Member | - | 12-07-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 93 265 000 | 54 049 529 ( 57,95 %) | 0 | 57,95 % |
Bedrijfsgegevens
![Adres Nymox Pharmaceutical Corporation](https://cdn.zonebourse.com/static/address/10305.png)
Sector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
+34,14% | 51,51 mld. | |
-6,54% | 39,03 mld. | |
+34,92% | 38,91 mld. | |
-12,11% | 26,68 mld. | |
+12,62% | 26,13 mld. | |
-13,43% | 19,91 mld. | |
+43,73% | 13,71 mld. | |
+31,81% | 12,38 mld. | |
-4,54% | 11,74 mld. |
- Beurs
- Aandelen
- Koers NYMXF
- Koers
- Onderneming Nymox Pharmaceutical Corporation